CNS International Prognostic Index: A Risk Model for CNS Relapse in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP.

@article{Schmitz2016CNSIP,
  title={CNS International Prognostic Index: A Risk Model for CNS Relapse in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP.},
  author={Norbert Schmitz and Samira Zeynalova and Maike Nickelsen and Roopesh Kansara and Diego Villa and Laurie H. Sehn and Bertram Glass and David W Scott and Randy D. Gascoyne and Joseph M. Connors and Marita Ziepert and Michael Pfreundschuh and Markus L{\"o}ffler and Kerry J. Savage},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2016},
  volume={34 26},
  pages={
          3150-6
        }
}
PURPOSE To develop and validate a risk score for relapse in the CNS in patients with diffuse large B-cell lymphoma (DLBCL). PATIENTS AND METHODS A total of 2,164 patients (18 to 80 years old) with aggressive B-cell lymphomas (80% DLBCL) treated with rituximab and CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone)-like chemotherapy, who were enrolled in studies from the German High-Grade Non-Hodgkin Lymphoma Study Group and the MabThera International Trial, were analyzed for… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 51 times over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 30 extracted citations

Similar Papers

Loading similar papers…